Opportunities, challenges, and difficulties in NMR-based metabolomics applied to neovascular age-related macular degeneration (nAMD) patient follow-up
IntroductionThis study applies NMR-based metabolomics to investigate neovascular age-related macular degeneration (nAMD), addressing challenges in patient management, disease progression evaluation, and treatment response assessment. A two-year follow-up of 29 nAMD patients undergoing treatment prov...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2024.1449226/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583619863904256 |
|---|---|
| author | M. Schoumacher M. Schoumacher V. Lambert M. Campas P. Blaise B. Locht M. Thys E. Duchateau E. Cavalier E. Cavalier J.-M. Rakic A. Noël P. de Tullio P. de Tullio |
| author_facet | M. Schoumacher M. Schoumacher V. Lambert M. Campas P. Blaise B. Locht M. Thys E. Duchateau E. Cavalier E. Cavalier J.-M. Rakic A. Noël P. de Tullio P. de Tullio |
| author_sort | M. Schoumacher |
| collection | DOAJ |
| description | IntroductionThis study applies NMR-based metabolomics to investigate neovascular age-related macular degeneration (nAMD), addressing challenges in patient management, disease progression evaluation, and treatment response assessment. A two-year follow-up of 29 nAMD patients undergoing treatment provided 231 time points for analysis.MethodsOver the two-year period, 11 males and 18 females (aged 61–92 years) were monitored, yielding 231 time points. At each time point, blood samples for NMR metabolomics analysis, clinical measurements (e.g., lactate, glucose levels, HDL/LDL cholesterol, and blood pH), and optical coherence tomography (OCT) images were collected to evaluate the progression of choroidal neovascularization. 1H-NMR metabolomic analysis led to the quantification of over 60 metabolites and of the major lipoprotein fractions. Both multivariate and univariate statistical approaches tailored for longitudinal data were employed to identify biomarkers correlating metabolomic changes with ocular alterations during disease progression.Results and DiscussionDespite a rigorous analytical workflow enabling precise quantification of over 60 metabolites and the application of advanced statistical tools for longitudinal data, achieving consistent results across the cohort proved challenging. The dataset’s heterogeneity, reflecting real-world clinical practice, complicated the derivation of global conclusions. Personalized analyses on a patient-by-patient basis successfully identified individual correlation models, but a universal model remained elusive. This study highlights the inherent challenges of translating findings from controlled settings into clinical practice, where factors such as visit frequency, treatment variability, and disease heterogeneity limit data uniformity. We emphasize the importance of experimental design in longitudinal studies, particularly when dealing with incomplete and variable datasets. We are therefore confident that, considering both the challenges and difficulties identified in this work and the preliminary results presented here, it is possible to develop predictive and individualized models for monitoring patients with nAMD. Such models could greatly assist clinicians in providing better care for these patients. |
| format | Article |
| id | doaj-art-cce758feffdc49e09556c91eee0afbfb |
| institution | Kabale University |
| issn | 2296-889X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj-art-cce758feffdc49e09556c91eee0afbfb2025-01-28T09:22:44ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2025-01-011110.3389/fmolb.2024.14492261449226Opportunities, challenges, and difficulties in NMR-based metabolomics applied to neovascular age-related macular degeneration (nAMD) patient follow-upM. Schoumacher0M. Schoumacher1V. Lambert2M. Campas3P. Blaise4B. Locht5M. Thys6E. Duchateau7E. Cavalier8E. Cavalier9J.-M. Rakic10A. Noël11P. de Tullio12P. de Tullio13Clinical Metabolomics Group (CliMe), Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, BelgiumDepartment of Medical Chemistry, University Hospital of Liège, Liège, BelgiumDepartment of Ophthalmology, University Hospital of Liège, Liège, BelgiumClinical Metabolomics Group (CliMe), Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, BelgiumDepartment of Ophthalmology, University Hospital of Liège, Liège, BelgiumDepartment of Ophthalmology, University Hospital of Liège, Liège, BelgiumDepartment of Ophthalmology, University Hospital of Liège, Liège, BelgiumDepartment of Ophthalmology, University Hospital of Liège, Liège, BelgiumClinical Metabolomics Group (CliMe), Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, BelgiumDepartment of Medical Chemistry, University Hospital of Liège, Liège, BelgiumDepartment of Ophthalmology, University Hospital of Liège, Liège, BelgiumLaboratory of Tumor and Development Biology, GIGA, Université de Liège, Liège, BelgiumClinical Metabolomics Group (CliMe), Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, BelgiumDepartment of Medical Chemistry, University Hospital of Liège, Liège, BelgiumIntroductionThis study applies NMR-based metabolomics to investigate neovascular age-related macular degeneration (nAMD), addressing challenges in patient management, disease progression evaluation, and treatment response assessment. A two-year follow-up of 29 nAMD patients undergoing treatment provided 231 time points for analysis.MethodsOver the two-year period, 11 males and 18 females (aged 61–92 years) were monitored, yielding 231 time points. At each time point, blood samples for NMR metabolomics analysis, clinical measurements (e.g., lactate, glucose levels, HDL/LDL cholesterol, and blood pH), and optical coherence tomography (OCT) images were collected to evaluate the progression of choroidal neovascularization. 1H-NMR metabolomic analysis led to the quantification of over 60 metabolites and of the major lipoprotein fractions. Both multivariate and univariate statistical approaches tailored for longitudinal data were employed to identify biomarkers correlating metabolomic changes with ocular alterations during disease progression.Results and DiscussionDespite a rigorous analytical workflow enabling precise quantification of over 60 metabolites and the application of advanced statistical tools for longitudinal data, achieving consistent results across the cohort proved challenging. The dataset’s heterogeneity, reflecting real-world clinical practice, complicated the derivation of global conclusions. Personalized analyses on a patient-by-patient basis successfully identified individual correlation models, but a universal model remained elusive. This study highlights the inherent challenges of translating findings from controlled settings into clinical practice, where factors such as visit frequency, treatment variability, and disease heterogeneity limit data uniformity. We emphasize the importance of experimental design in longitudinal studies, particularly when dealing with incomplete and variable datasets. We are therefore confident that, considering both the challenges and difficulties identified in this work and the preliminary results presented here, it is possible to develop predictive and individualized models for monitoring patients with nAMD. Such models could greatly assist clinicians in providing better care for these patients.https://www.frontiersin.org/articles/10.3389/fmolb.2024.1449226/fullage-related macular degenerationmetabolomicsNMRpersonalized and precision medicinebiomarkers |
| spellingShingle | M. Schoumacher M. Schoumacher V. Lambert M. Campas P. Blaise B. Locht M. Thys E. Duchateau E. Cavalier E. Cavalier J.-M. Rakic A. Noël P. de Tullio P. de Tullio Opportunities, challenges, and difficulties in NMR-based metabolomics applied to neovascular age-related macular degeneration (nAMD) patient follow-up Frontiers in Molecular Biosciences age-related macular degeneration metabolomics NMR personalized and precision medicine biomarkers |
| title | Opportunities, challenges, and difficulties in NMR-based metabolomics applied to neovascular age-related macular degeneration (nAMD) patient follow-up |
| title_full | Opportunities, challenges, and difficulties in NMR-based metabolomics applied to neovascular age-related macular degeneration (nAMD) patient follow-up |
| title_fullStr | Opportunities, challenges, and difficulties in NMR-based metabolomics applied to neovascular age-related macular degeneration (nAMD) patient follow-up |
| title_full_unstemmed | Opportunities, challenges, and difficulties in NMR-based metabolomics applied to neovascular age-related macular degeneration (nAMD) patient follow-up |
| title_short | Opportunities, challenges, and difficulties in NMR-based metabolomics applied to neovascular age-related macular degeneration (nAMD) patient follow-up |
| title_sort | opportunities challenges and difficulties in nmr based metabolomics applied to neovascular age related macular degeneration namd patient follow up |
| topic | age-related macular degeneration metabolomics NMR personalized and precision medicine biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2024.1449226/full |
| work_keys_str_mv | AT mschoumacher opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT mschoumacher opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT vlambert opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT mcampas opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT pblaise opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT blocht opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT mthys opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT educhateau opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT ecavalier opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT ecavalier opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT jmrakic opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT anoel opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT pdetullio opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup AT pdetullio opportunitieschallengesanddifficultiesinnmrbasedmetabolomicsappliedtoneovascularagerelatedmaculardegenerationnamdpatientfollowup |